Kantum Bio kantumbio.com


Kantum Diagnostics, dba Kantum Bio, is developing two programs in parallel: (1) Selective receptor antagonist-based therapeutics for AKI and (2) a UDP-G diagnostic test. Kantum's lead therapeutic development candidate, KB-1801, will be developed for the prophylaxis and treatment of AKI secondary to cardiovascular intervention. Furthermore, KB-1801 has potential in cardiovascular accidents and other conditions associated with AKI in the ICU (e.g. sepsis, polytrauma, nephrotoxicity). The UDP-G dia...Show all

Kantum Diagnostics, dba Kantum Bio, is developing two programs in parallel: (1) Selective receptor antagonist-based therapeutics for AKI and (2) a UDP-G diagnostic test. Kantum's lead therapeutic development candidate, KB-1801, will be developed for ...Show all

Company (Alive / Active)

Phone:

Fax:

75 S Main St #7-160

Concord, 03301
New Hampshire, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Kantum Bio $1.8M Oct 12, 2018

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Kantum Bio Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 2 investors
There is no Board of Directors data available for this company. Please select another tab.
There is no Competitors data available for this company. Please select another tab.

Patents

Title Application Date Patent Date Status
(Patent / Application)